Effect of a unique constant-estrogen, pulsed-progestin hormone replacement therapy containing 17β-estradiol and norgestimate on endometrial histology

International Journal of Fertility and Women's Medicine

Volumn 44, Issue 6, 1999, Pages 279-285

  Corson, Stephen L ^a   Richart, Ralph M ^b   Caubel, Patrick ^c   Pilar, Lim ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Columbia Univ Coll Phys Surgs ^*  (United States)

^c R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

17 estradiol; Endometrial hyperplasia; Estrogen; Hormone replacement therapy; Menopause; Norgestimate; Progestin; Progestogen

Indexed keywords

ESTRADIOL; ESTROGEN; FOLLITROPIN; GESTAGEN; NORGESTIMATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIUM; ESTRADIOL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERPLASIA; MIDDLE AGED; NORGESTREL; POSTMENOPAUSE; UNITED STATES;

EID: 0033377526     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Hormone-replacement therapy. Weighing the benefits and risks. Harv Health Lett 22:1-3, 1997.
2. Session DR, Kelly AC, Jewelewicz R: Current concepts in estrogen replacement therapy in the menopause. Fertil Steril 59:277-284, 1993.
3. Larson B, Collins A, Landgren BM: Urogenital and vasomotor symptoms in relation to menopausal status and the use of hormone replacement therapy (HRT) in healthy women during transition to menopause. Maturitas 28:99-105, 1997.
4. Riggs BL, Melton LJ: The prevention and treatment of osteoporosis. N Engl J Med 327:620-627, 1992.
5. The Writing Group for the PEPI Trial: Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 276:1389-1396, 1996.
6. Calle EE, Miracle-McMahill HL, Thun MJ, et al: Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 87:517-523, 1995.
7. Fernandez E, La Vecchia C, Franceschi S, et al: Oral contraceptive use and risk of colorectal cancer. Epidemiology 9:295-300, 1998.
8. Selzman CH, Whitehill TA, Shames BD, et al: The biology of estrogen-mediated repair of cardiovascular injury. Ann Thorac Surg 65:868-874, 1998.
9. Collins P: Vascular aspects of oestrogen. Maturitas, 23:217-226, 1996.
10. Beckmann CRB: Alzheimer's disease: an estrogen link? Curr Opin Obstet Gynecol 9:295-299, 1997.
11. Tang M-X, Jacobs D, Stern Y, et al: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348:429-432, 1996.
12. Shaywitz SE, Shaywitz BA, Pugh KR, et al: Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 281:1197-1202, 1999.
13. Sherwin BB: Estrogen and cognitive functioning in women. Proc Soc Exp Biol Med 217:17-22, 1998.
14. Ditkoff EC, Crary WG, Cristo M, et al: Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 78:991-995, 1991.
15. Samsioe G: Hormone replacement therapy: aspects of bleeding problems and compliance. Int J Fertil 41:11-15, 1996.
16. Leavitt WW, Okulicz WC, McCracken JA, et al: Rapid recovery of nuclear estrogen receptor and oxytocin receptor in the ovine uterus following progesterone withdrawal. J Steroid Biochem 22:687-691, 1985.
17. Bayard F, Damilano S, Robel P, et al: Cytoplasmic and nuclear estradiol and progesterone receptors in human endometrium. J Clin Endocrinol Metab 46:635-648, 1978.
18. Eckert RL, Katzenellenbogen BS: Human endometrial cells in primary tissue culture: modulation of the progesterone receptor level by natural and synthetic estrogens in vitro. J Clin Endocrinol Metab 52:699-708, 1981.
19. Cano A, Serra V, Rivera J, et al: Expression of estrogen receptors, progesterone receptors, and an estrogen receptor-associated protein in the human cervix during the menstrual cycle and menopause. Fertil Steril 54:1058-1064, 1990.
20. Whitehead MI, Townsend PT, Pryse-Davies J, et al: Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 305:1599-1605, 1981.
21. West NB, Brenner RM: Progesterone-mediated suppression of estradiol receptors in cynomolgus macaque cervix, endometrium and oviduct during sequential estradiol-progesterone treatment. J Steroid Biochem 22:29-37, 1985.
22. Clark JH, Hsueh AJ, Peck EJ, Jr: Regulation of estrogen receptor replenishment by progesterone. Ann NY Acad Sci 286:161-179, 1977.
23. Hsueh AJW, Peck EJ, Jr, Clark JH: Control of uterine estrogen receptor levels by progesterone. Endocrinology 98:438-444, 1976.
24. Tseng L, Gurpide E: Effects of progestins on estradiol receptor levels in human endometrium. J Clin Endocrinol Metab 41: 402-404, 1975.
25. Breckwoldt M, Keck C, Karck U: Benefits and risks of hormone replacement therapy (HRT). J Steroid Biochem Mol Biol 53:205-208, 1995.
26. Woodruff JD, Pickar JH: Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 170:1213-1223, 1994.
27. The Writing Group for the PEPI Trial: Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Inverventions (PEPI) Trial. JAMA 275:270-375, 1996.
28. Weinstein L: Efficacy of a continuous estrogen-progestin regimen in the menopausal patient. Obstet Gynecol 69:929-932, 1987.
29. Sulak PJ: Endometrial cancer and hormone replacement therapy. Appropriate use of progestins to oppose endogenous and exogenous estrogen. Endocrinol Metab Clin North Am 26:399-412, 1997.
30. Hulley S, Grady D, Bush T, et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613, 1998.
31. Udoff L, Langenberg P, Adashi EY: Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 76:30-316, 1995.
32. Panay N, Studd J: Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update 3:159-171, 1997.
33. Casper RF, Chapdelaine A: Estrogen and interrupted progestin: a new concept for menopausal hormone replacement therapy. Am J Obstet Gynecol 168:1188-1194, 1993.
34. Casper RF: Regulation of estrogen/progestogen receptors in the endometrium. Int J Fertil 41:16-21, 1996.
35. Langer RD, Pierce JJ, O'Hanlan KA, et al: Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. N Engl J Med 337:1792-1798, 1997.
36. Rom DM, Costello RJ, Connell LT: On closed test procedures for dose-response analysis. Stat Med 13:1583-1596, 1994.
37. Jick H, Watkins RN, Hunter JR, et al: Replacement estrogens and endometrial cancer. N Engl J Med 300:218-222, 1979.
38. Whitehead MI, Hillard TC, Crook D: The role and use of progestogens. Obstet Gynecol 75(suppl):59S-76S, 1990.